Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 230-745-9 | CAS number: 7300-34-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
LD50 oral = 3450 mg/kg (BASF, 1972; OECD401)
LC50 inhalation (4h, aerosol) = 1.5 mg/L (BASF1980; OECD403)
LD50 dermal > 1000 (male ) and > 2000 mg/kg (female) (BASF 2001; OECD402)
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Principles of method if other than guideline:
- In principle, the methods described in the OECD Guideline 401 were used. Young adult laboratory rats were purchased from breeder. Usually the source and strain of animals were not documented. Several groups of 5 rats per sex and dose were treated simultaneously by gavage with preparations of the test substance in suitable vehicle. The concentrations of these preparations were used to achieve comparable volumes per kg body weight. Group-wise documentation of clinical signs was performed over the 7 day study period. Body weight was determined before the start of the study only, as it was needed for determination of dose.
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- not specified
- Sex:
- male/female
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- 2% aqueous solution
- Doses:
- 7200, 5600, 4500, 3600, 2800 and 2250 mg/kg bw
- No. of animals per sex per dose:
- 5 per sex and dose
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 7 days;
- The animals were observed for mortality and clinical signs of toxicity;
- Frequency of observations: Several times on the application day, thereafter once each working day;
- Body weights were only recorded at the beginning of the study;
- Necropsy of survivors and animals which died performed: yes - Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- ca. 3 450 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: calculated from original value ca. 3600 µl/kg bw using density of 0.96 g/cm³
- Mortality:
- see table below
- Clinical signs:
- other: No symptoms monitored in rats
- Gross pathology:
- Dead animal: dilatation of the heart, stomach filled with liquid and dilated; extensive hemorrhagic erosions; sanguineous, diarrhetic stomach content
Surviving animals: no findings - Interpretation of results:
- Category 5 based on GHS criteria
Reference
Mortality data:
Dose [cmm/kg] |
Mortality |
|
Male |
Female |
|
7200 |
5/5 |
5/5 |
5600 |
5/5 |
5/5 |
4500 |
4/5 |
4/5 |
3600 |
2/5 |
2/5 |
2800 |
0/5 |
0/5 |
2250 |
1/5 |
1/5 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 3 450 mg/kg bw
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
- Specific details on test material used for the study:
- - Analytical purity: approximately 99%
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: MUS RATTUS, Brunnthal
- Weight at study initiation: 185 + 15 g
- Diet: Herilan MRH
- Water: ad libitum - Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose/head only
- Vehicle:
- air
- Details on inhalation exposure:
- The test substance was applied in a constant quantity with the help of an infusion pump to a 2-step blast pipe. Synthetic air (2.6 bar) was used to generate an aerosol, which was infused into the system.
- Analytical verification of test atmosphere concentrations:
- yes
- Duration of exposure:
- 4 h
- Concentrations:
- 22.9, 10.01, 2.19 and 0.41 [mg/L] (nominal concentration)
3.72, 1.76, 0.81, 0.17 [mg/L] (analytic concentration) - No. of animals per sex per dose:
- 10
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: weekly
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight,organ weights, histopathology, other: - Statistics:
- according to D.J. Finney (D..J*. Finney; Probitanalysis 1971, Seite 1 - 150). Published by the Syndics of the Cambridge University Press, Bentley House, 200 Euston Road, London N.W. 1
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- 1.5 mg/L air
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Mortality:
- see table below; the animals died within 1-5 days after test item application
- Clinical signs:
- other: 3.72, 1.76 [mg/L] (analytic concentration): reddish head, dyspnea, scrubby, shaggy fur, tremor 0.81 [mg/L] (analytic concentration): accelerated respiration 0.17 [mg/L] (analytic concentration): nothing abnormal detected Surviving animals did either not
- Body weight:
- The only male animal surviving exposure to 3.75 mg/l showed a significantly reduced body weight; furthermore, males at 1.76 mg/l showed some reduction on body weight, whereas all other animals exhibited body weights similar to control animals 14 days subsequent to exposure. (see table below)
- Gross pathology:
- heart: acute dilatation
lung: strong hyperemia
kidney: some animals showed tubule necrosis - Interpretation of results:
- Category 4 based on GHS criteria
Reference
Analytic concentration |
Nominal concentration |
Mortality males |
Mortality females |
3,72 |
22,9 |
9/10 |
10/10 |
1,76 |
10,01 |
6/10 |
6/10 |
0,81 |
2,19 |
0/10 |
3/10 |
0,17 |
0,41 |
0/10 |
0/10 |
Analytic concentration |
Mean body weight d0 |
Mean body weight d7 |
Mean body weight d14 |
|||
|
males |
females |
males |
females |
males |
females |
3,72 |
186 (10) |
183 (10) |
124 (1) |
all dead |
151 (1) |
all dead |
1,76 |
179 (10) |
180 (10) |
211 (4) |
181 (4) |
238 (4) |
214 (4) |
0,81 |
179 (10) |
179 (10) |
213 (10) |
186 (7) |
266 (10) |
207 (7) |
0,17 |
182 (10) |
180 (10) |
225 (10) |
201 (10) |
269 (10) |
214 (10) |
Control |
182 (10) |
182 (10) |
218 (10) |
199 (10) |
264 (10) |
213 (10) |
The number in brackets indicates the number of animals alive at the respective time point.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 1 500 mg/m³ air
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
- Specific details on test material used for the study:
- - Purity: 99.7 %
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Boehringer Ingelheim Pharma KG
- Age at study initiation: young adult animals
- Weight at study initiation: 200-300 g +/- 20% of the mean weight
- Housing: single housing
- Diet (e.g. ad libitum): Kliba-Labordiaet ad libitumn
- Water (e.g. ad libitum): Tap water ad libitumn per day.
- Acclimation period: at least one week
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24°C
- Humidity (%): 30-70%
- Photoperiod (hrs dark / hrs light): 12/12 - Type of coverage:
- semiocclusive
- Vehicle:
- water
- Details on dermal exposure:
- The test item solution was administered to about 50 cm2 (corresponds to at least 10 % of the body surface area) of the previously clipped skin (dorsal and dorsolateral parts of the trunk); following 24 h incubation with the test item, the dressing was removed and the application site rinsed with warm water
- Duration of exposure:
- 24 h
- Doses:
- female: 400, 1000 and 2000 mg/kg
male: 400 and 1000 mg/kg - No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- animals were observed for 14 days
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Remarks on result:
- other: no mortality occurred
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- > 1 000 mg/kg bw
- Remarks on result:
- other: no mortality occurred
- Mortality:
- No mortalities occured at any dose level
- Clinical signs:
- other: No systemic signs of toxicity were noted in all animals.
- Gross pathology:
- Local effects observed in the 400, 1000 and 2000 mg/kg dose group comprised very slight to severe erythema, very slight or slight edema, scaling, crust formation, bleeding and eczematous skin changes. Additionally, necrosis was observed in the 2000 mg/kg dose group. Due to severe local effects in the female animals of the 2000 mg/kg dose group no further investigation at this dose level was performed in male animals.
- Other findings:
- Necropsy findings of 4 female animals of the 2000 mg/kg dose group and 1 female animal of the 1000 mg/kg dose group sacrificed at the end of the study comprised several focal skin lesions in the region of the application site, crust formation at the surface and slight focal erythema. No abnormalities were observed in all other animals sacrificed at the end of the study.
The necrotic skin changes in female animals of the 2000 mg/kg dose group assessed by histo-pathological examination indicating full thickness necrosis. - Interpretation of results:
- Category 5 based on GHS criteria
- Conclusions:
- Under the conditions of this study the acute dermal median lethal dose (LD50) of the test substance was found to be greater than 2000 mg/kg bw for female rats and greater than 1000 mg/kg bw for male rats. Due to the severe local effects (necrosis) observed at the dose level of 2000 mg/kg bw in the female rats no higher dose levels were assessed in male rats. However, due to lacking systemic effects the acute dermal median lethal dose (LD50) of the test substance is very likely to be greater than 2000 mg/kg bw also in the male animals.
- Executive summary:
The study was performed to determine the acute dermal median lethal dose (LD50) of the test substance, applied as a solution in doubly distilled water, in Wistar rats.
The study procedure was based on the EEC, OECD and EPA/OPPTS guidelines.
The test material was applied as a solution in doubly distilled water to the clipped epidermis (dorsal and dorsolateral parts of the trunk) and was covered by a semiocclusive dressing for 24 hours. Dose levels of 400 and 1000 mg/kg bw were applied to groups of 5 male and female rats each. 2000 mgkg bw were given to 5 female rats.
No systemic signs of toxicity were noted in all animals.
The expected body weight gain was generally observed in the course of the study, with the exception of 2 female animals of the 2000 mg/kg bw dose group, which showed stagnation of body weight in the first week of observation.
Local effects observed in the 400, 1000 and 2000 mg/kg bw dose group comprised very slight to severe erythema, vry slight edema, scaling, crust formation, bleeding and eczematoid skin change. In the 2000 mg/kg bw dose group additionally necrosis was observed. Due to severe local effects in the female animals of th 2000 mg/kg bw dose group no further investigation at this dose level was performed in male animals.
No mortality occurred.
Necropsy findings of 4 female animals of the 2000 mg/kg bw dose group and 1 female animal of the 1000 mg/kg bw dose group sacrificed at the end of the study comprised several focal skin lesions in the region of the application site, crust formation at the surface and slight focal erythema. No abnormalities were observed in all other animals sacrificed at the end of the study.
The necrotic skin changes in female animals of the 2000 mg/kg bw dose group assessed by histopathological examination indicating full thickness necrosis.
Under the conditions of this study the acue dermal median lethal dose (LD50) of the test substance was found to be greater than 2000 mg/kg bw for female rats and greater than 1000 mg/kg bw for male rats. Due to the severe local effects (necrosis) observed at the dose level of 2000 mg/kg bw in the female rats no higher dose levels were assessed in male rats. However, due to lacking systemic effects the acute dermal median lethal dose (LD50) of the test substance is very likely to be greater than 2000 mg/kg bw also in the male animals.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Additional information
Acute oral toxicity:
The acute oral toxicity of the test item was assessed similar to OECD401 (BASF AG, 1972). Five rats per dose were given the test item at a 2% aqueous solution once per oral gavage. Animals were observed for seven days and mortality as well clinical signs were monitored. All animals died following application of the two highest doses (i.e. 7200 and 5600 mg/kg), 4/5 males and all female rats at 4500 mg/kg, 2/5 males and 3/5 females at 3600 mg/kg, 0/5 males and 1/5 females at 2800 mg/kg and 1/5 males and 0/5 females at 2250 mg/kg. No clinical signs were noted in the rats; Findings at gross pathology included dilatation of the heart, stomach filled with liquid and dilated, extensive hemorrhagic erosions as well as sanguineous, diarrheic stomach content. Based on these results, the oral LD50 was calculated as 3450 mg/kg for males and females.
Acute inhalation toxicity:
The acute inhalation toxicity of the test item was assessed similar to OECD403. The test substance was applied in a constant quantity with the help of an infusion pump to a 2-step blast pipe. Synthetic air (2.6 bar) was used to generate an aerosol, which was infused into the system. Sprague-Dawley rats were exposed for 4 hrs via the nose/head-only exposure method. Analytic concentrations were 3.72, 1.76, 0.81, 0.17 mg/l. Animals were observed up to 14 days following exposure and clinical signs and symptoms monitored regularly. 9/10 males and 10/10 females died when exposed to 3.72 mg/l, 6/10 males and females at 1.76 mg/l, 0/10 males and 3/10 females at 0.81 mg/l and no animals at 0.17 mg/l. Clinical signs at 3.72 and 1.76 mg/l included reddish head, dyspnea, scrubby, shaggy fur and tremor; at 0.81 mg/l accelerated respiration. No clinical signs were noted at 0.17 mg/L. The only male animal surviving exposure to 3.75 mg/l showed a significantly reduced body weight; furthermore, males at 1.76 mg/l showed some reduction on body weight, whereas all other animals exhibited body weights similar to control animals 14 days subsequent to exposure. Animals that died suffered from acute dilatation of the right heart chamber and strong hyperemia of the lung; furthermore, some animals showed tubule necrosis of the kidney. The clinical effects and the pathological findings in the lung can be attributed to the local toxicity caused by the corrosiveness of the test substance. The other pathological findings are considered to be secondary to the observed lung damage. Using the statistical method described by Finley et al. (1971), the LC50 was calculated as 1.5 mg/L.
In two older studies (BASF AG 1972; BASF AG, 1979) six rats per sex were exposed to a saturated atmosphere of the test substance for 8 hours (inhalation risk test). Mortality did not occur. Accelerated breathing and irritation of the mucosa were observed as clinical signs.
Acute dermal toxicity:
The acute dermal toxicity of the test item was assessed according to OECD402. The test item solution was administered to about 50 cm2 (corresponds to at least 10 % of the body surface area) of the previously clipped skin (dorsal and dorsolateral parts of the trunk) of Wistar rats as semi-occlusive coverage. 24 h later, the dressing was removed and the application site rinsed with warm water to remove residual amounts of the test item. Animals were observed for 14 days. No mortalities occurred at any dose level (up to 2000 mg/kg for females and 1000 mg/kg males). Local effects observed in the 400, 1000 and 2000 mg/kg dose group (females) comprised very slight to severe erythema, very slight or slight edema, scaling, crust formation, bleeding and eczematous skin changes. Additionally, necrosis was observed in the 2000 mg/kg dose group. Due to severe local effects in the female animals of the 2000 mg/kg dose group no further investigation at this dose level was performed in male animals. No systemic clinical signs of toxicity were noted in all animals. Necropsy findings of 4 females of the 2000 mg/kg dose group and 1 female of the 1000 mg/kg dose group sacrificed at the end of the study comprised several focal skin lesions in the region of the application site, crust formation at the surface and slight focal erythema. No abnormalities were observed in all other animals sacrificed at the end of the study. Taken together, the test item does not depict any risk of systemic dermal toxicity and the LD50 is > 1000 mg/kg in males (highest dose tested) and > 2000 mg/kg in females.
There are two older acute dermal toxicity studies available (one in rats, one in rabbits; BASF AG, 1978 and BASF AG, 1979). However, these studies were disregarded for assessment due to methodological deficiencies.
Acute intraperitoneal toxicity:
In an acute toxicity study (BASF AG, 1972) the undiluted test substance was administered to 5 mice per sex via intraperitoneal injection at dose levels of 100, 125, 160, 200, 250, 320 and 400 µL/kg bw. Observation period was until day 14 following treatment. All animals of the highest four dose groups died. Clinical signs were observed like apathy, dyspnoe, and tremor. Gross pathology revealed hyperaemia in the liver and intraabdominal adhesions. Based on the mortality incidences of 0/10, 5/10, 4/10, 10/10, 10/10, 10/10, and 10/10 noted at 100, 125, 160, 200, 250, 320 and 400 µL/kg bw, respectively, the LD50 for the i.p. route of exposure was considered to be approximately 125 µL/kg bw (corresponding to approx. 120 mg/kg bw based on the test substance density of 0.96 g/cm³).
Justification for classification or non-classification
According to Regulation (EC) No 1272/2008 (CLP), the registered substance is classified as acute inhalation toxic category 4 and labelled with "Warning" and H332 "harmful if inhaled".
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.